Roving Reporter Asks: Where Do You See the Most Progress in CGT Manufacturing and Scalability? - Summary - MDSpire

Roving Reporter Asks: Where Do You See the Most Progress in CGT Manufacturing and Scalability?

  • May 6, 2026

Share

Objective:

To gather insights on advancements in cell and gene therapy (CGT) manufacturing and scalability from industry experts.

Key Findings:
  • Significant progress in manufacturing processes for CGT.
  • Improvements in scalability are enhancing the ability to translate innovations into practical applications.
  • Collaboration among industry players is crucial for overcoming manufacturing challenges.
Interpretation:

The advancements in CGT manufacturing and scalability are pivotal for the future of therapeutic applications, indicating a shift towards more efficient production methods.

Limitations:
  • Insights are based on subjective opinions from industry representatives.
  • The scope of progress may vary significantly across different CGT applications.
Conclusion:

The discussions highlight a positive trend in CGT manufacturing and scalability, suggesting a promising future for therapeutic innovations.

Original Source(s)

Roving Reporter Asks: Where Do You See the Most Progress in CGT Manufacturing and Scalability?

  • May 6, 2026

Related Content

Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer

Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients w...

Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL

In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL).

Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases

In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intrave...